Clinical Trials Browser

Waldenstrom Macroglobulinemia × Bortezomib × 90 days × Clear all

NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Phase 2 Active not recruiting

46 enrolled 10 charts

Waldenstrom Macroglobulinemia